Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Billerica battery startup ...
The two companies agreed to cooperate in the development of all-solid-state battery materials. In sample testing of materials from multiple suppliers, POSCO Future M demonstrated good rate capability.
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. In this episode, Thomas Betts chats with ...
'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...
Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results